β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development
β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development is a paper indexed in ScholarIQ from OpenAlex.
How many citations does β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development have?
β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development has 48 citations in the OpenAlex counts ScholarIQ stores.
When was β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development published?
β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development has 2021 year in the ScholarIQ index.
What is the open-access status of β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development?
β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development has green oa status in the ScholarIQ index.
What is the DOI of β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development?
The DOI for β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development is on the source record.
What is the PMID of β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development?
The PMID for β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development is on the source record.
What is the OpenAlex record for β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development?
The OpenAlex for β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development is on the source record.